In DNA vaccination, CD4
INTRODUCTION

Cytotoxic CD8
þ T cells (CTLs) are the most important effector cells in the anti-tumor immunity, but CD4 þ T cells that markedly contribute to their stimulation play an irreplaceable role in this response. CD4
þ T helper cells (T h ) are usually required for the priming and expansion of CD8 þ T cells and generation of memory CD8 þ T cells. They are also involved in the infiltration of tumors by CD8 þ T cells. The CD4 þ T-cell help is especially beneficial for the induction of immunity against tumor antigens with low expression and/or 'self' character when CTLs are deleted or tolerized. 1 To enhance the CD4 þ T-cell help induced by DNA vaccines, various strategies have been developed. 2 One of them is the fusion of a gene encoding an immunization protein with a foreign gene or its part providing T h epitopes. Genes from pathogenic microbes are usually utilized as foreign genes for this purpose. Helper epitopes of the tetanus toxin (TT) produced by Clostridium tetani have been extensively analyzed. Some of the TT helper epitopes have been shown to bind several human and mouse major histocompatibility complex (MHC) class II molecules. [3] [4] [5] Therefore, these 'promiscuous' ('universal') epitopes are used for the improvement of antitumor vaccines and they have also been demonstrated to overcome the tolerance to tumor self-antigens. 6 Moreover, the activation of CD4 þ T cells increases the immunity against weak tumor antigens.
TT is a relatively long protein (435 aa) containing a number of CD8 epitopes that can potentially interfere with the induction of immune reactions against tumor antigens. Indeed, such interference has already been reported in mice. 7 On the other hand, the utilization of minimal helper epitopes including a 'universal' TT epitope in DNA vaccines failed to stimulate CD4 þ T cells in some experimental systems. 7, 8 In an alternative approach, Pan DR epitope (PADRE) peptides with a high affinity for both human and mouse MHC class II molecules and the ability to activate CD4 þ T cells were designed in silico and their immunogenicity was confirmed both in vitro and in vivo. 9 The PADRE helper epitope has also proved its potency in DNA immunization. 10, 11 MHC class II molecules bind peptides about 10-30 residues long (12-16 residues being the optimal length). Residues flanking helper epitopes in a protein antigen substantially influence the immunogenicity of the epitopes. 12 The key factor that affects the proteolytic processing of antigens and generation of peptides carrying helper epitopes is probably the conformational flexibility that correlates with the presence of protease-sensitive sites. 13 In this study, we used the potent 'universal' p30 helper epitope from TT for the modification of DNA vaccines based on the E7 antigen from human papillomavirus type 16 (HPV16) and examination of conditions that influence its effect on the induction of the CTL response after delivery of DNA vaccines via a gene gun. Our results suggest that the cellular localization of the modified antigens was crucial for the impact of the p30 epitope which was associated with the activation of T h 2 response. In comparison, the effect of the stronger PADRE epitope was not markedly affected by the cellular localization.
RESULTS
Modification of DNA vaccines with the p30 helper epitope
To study the effect of a helper epitope on the CTL response induced by gene gun DNA immunization, we utilized the widely used strong p30 helper epitope from TT and the oncoprotein E7 from HPV16 mutated in the pRb-binding site (E7GGG).
14 The p30 epitope was introduced into three forms of E7GGG that differ in the cellular localization: (i) E7GGG is localized into the nuclei and cytoplasm; (ii) Sig.E7GGG (containing the signal peptide from lysosomalassociated membrane protein 1, LAMP-1) is translocated into the endoplasmic reticulum; and (iii) Sig.E7GGG.LAMP (moreover carrying the C-terminus of LAMP-1) is further translocated through the Golgi apparatus into the endosomes and lysosomes.
As the proteolytic cleavage of antigens and the generation of peptides carrying helper epitopes are dependent on the protein conformation and it has been shown that the fusion of MHC class I-restricted epitopes with a C-terminus of the carrier protein enhanced the CTL response, 15 p30 was fused with both ends of E7GGG, which could also facilitate its proper processing and presentation with MHC class II molecules.
Furthermore, residues flanking helper epitopes can affect the generation of immunogenic peptides. They should contain protease-sensitive sites accessible to digestion as described in the model of CD4 þ T-cell epitope generation and presentation. 16 For the p30 epitope, such flanking regions can be predicted from the data of the relative crystallographic B factor calculated for fragment H c of TT. 17 Thus, DNA vaccines derived from the E7GGG gene were modified not only with the sequence encoding p30 (aa 947-967, short form designated TT1s) but also with the enlarged sequence carrying potential protease-cleavege sites (aa 936-975, long form TT1l).
The constructs with the p30 epitope are shown in Figure 1 . The production of the fusion proteins was verified by immunoblotting analysis (Figure 2a ). The insertion of TT1s or TT1l did not change the cellular localization of the fusion proteins in comparison with the parental ones (Figure 2b ).
The p30 epitope enhanced the E7-specific response only for the nuclear/cytoplasmic localization of antigens The immunogenicity of DNA vaccines modified by the insertion of sequences encoding the p30 epitope was compared in the enzyme-linked immunospot (ELISPOT) assay detecting interferon-g (IFN-g) production in lymphocytes isolated from the spleens. The activation of CD8 þ T cells specific for the E7 oncoprotein was determined after stimulation with the E7 49-57 peptide representing the immunodominant H-2D b -restricted epitope, and the activation of p30-recognizing CD4 þ T cells was examined after stimulation with the TT 947-967 peptide ( Figure 3 ). Significant enhancement of the CTL response against E7 was observed only for the fusion genes with the nuclear/cytoplasmic localization of their products. This effect was associated with the induction of p30-specific T-cell immunity and was found for both positions of TT1s, but only for the N-terminal-E7GGG fusion of TT1l (Figure 3a) . When the Sig.E7GGG protein was modified with p30, both N-terminal fusions induced a slightly increased CTL response, but this effect was insignificant and was not associated with the immune response against the helper epitope (Figure 3b ). The insertion of TT1s or TT1l into Sig.E7GGG.LAMP resulted in a weak p30-specific reaction that was not accompanied by the enhancement of the E7-specific response (Figure 3c) .
The antitumor efficacy of DNA vaccines was compared in therapeutic immunization against oncogenic TC-1 cells producing the E7 oncoprotein (Figure 4 ). Tumor growth was reduced only after the fusion of p30 with E7GGG. This effect was insignificant, but all mice immunized with the E7GGG gene developed tumors, while after the treatment with TT1s.E7GGG, TT1l.E7GGG or E7GGG.TT1s, a portion of animals remained without tumors ( Figure 4a ). The low improvement of the antitumor response was probably caused by a relatively stringent conditions used for this examination as first immunization was performed 3 days after inoculation of TC-1 cells that developed tumors in about 2 weeks in nonimmunized animals (see also Figure 7 ). The addition of the p30 epitope did not enhance the antitumor effect of Sig.E7GGG ( Figure 4b ) and Sig.E7GGG.LAMP ( Figure 4c ) constructs, in accordance with the conclusions drawn from the ELISPOT assay. Our results suggest that the effect of the p30 epitope was mainly influenced by the cellular localization of antigens. Their translocation into the endoplasmic reticulum and the endo/lysosomal compartment did not lead to the enhancement of the E7-specific response achieved for the nuclear/cytoplasmic localization. The addition of flanking regions to the inserted p30 epitope did not support induction of the immune response against this epitope.
The p30 epitope enhanced the T h 2 response to antigens translocated from the cytoplasm To study the cytokine profile of induced T h cells, the secretion of 12 cytokines was first screened with the Qiagen Multi-Analyte ELISArray after a 6-day restimulation with the TT 946-967 peptide ( Figure 5a ). In comparison with a negative control, augmented production was found for interleukin-13 (IL-13), IL-10, IFN-g, IL-17A and IL-5. The T h 1 response was then monitored by the evaluation of IFN-g production, and the T h 2 response was determined by the quantification of IL-10 and IL-13 cytokines (Figure 5b ). The fusion proteins carrying the p30 epitope (constructs with TT1l were used for this analysis) induced increased production of IFN-g for all three cellular localizations (this effect was statistically significant for TT1l.E7GGG and Sig.TT1l.E7GGG.LAMP). Both constructs translocated from the cytoplasm (that is, Sig.TT1l.E7GGG and Sig.TT1l.E7GGG.LAMP) also induced significant secretion of IL-10 and IL-13. Thus, the enhanced T h 2 response could be responsible for the failure of the helper p30 epitope to augment the response against the E7 antigen after gene gun immunization with the corresponding genes.
The PADRE epitope enhanced the E7-specific response for all cellular localizations of the fusion proteins To see whether the conclusions made for the p30 epitope and different cellular localization of fusion antigens can be generalized, we prepared the fusion genes PADRE.E7GGG, Sig.PADRE.E7GGG and Sig.PADRE.E7GGG.LAMP containing the sequence encoding the PADRE helper epitope and we compared their immunization efficacy with the corresponding genes without a helper epitope and with the TT1l sequence. The measurement of IFN-g production by the ELISPOT assay showed comparable induction of the PADRE-specific reaction for all three genes that was about twice as high compared with the response activated by p30 in TT1l.E7GGG (Figure 6a ). This reaction was accompanied by a significantly increased immunity against the E7 antigen that was most evident for PADRE.E7GGG (Figure 6b) . Similarly, in therapeutic immunization against TC-1cells, the PADRE epitope enhanced the antitumor effect for all tested cellular localizations of the E7 protein ( Figure 7) .
The comparison of cytokine concentrations after restimulation with the TT 946-967 and PADRE peptides showed at least 10-fold higher production of IFN-g for the constructs with the PADRE epitope (Figure 8a ). On the contrary, these fusion genes induced significantly lower production of IL-13 than the genes carrying the TT1l sequence (Figure 8b ). These results suggest that the PADRE epitope is more potent in stimulating T h 1 immunity in C57BL/6 mice than the p30 epitope. A remarkable enhancement of the E7-specific response was achieved for all three cellular localizations of the fusion proteins with PADRE. DISCUSSION DNA vaccination showed high efficacy in various preclinical disease models, but the results of initial clinical trials were disappointing. Continuing advances in the development of DNA vaccines and their delivery have resulted in the licensing of three veterinary DNA vaccines and promising results have also been reported for human subjects. 18 Still, further improvements are necessary to achieve sufficient antitumor efficacy of DNA vaccination. T h response optimization is important for a strong CTL response especially after immunization against tumorassociated antigens that represent tolerizing self-antigens. 19 Besides electroporation, administration of DNA vaccines into the skin including biolistic delivery via a gene gun is among the preferred methods of immunization with plasmid DNA. 20 In this study, we evaluated several parameters that can affect the processing and presentation of a foreign helper epitope and subsequently stimulation of CD4 þ and CD8 þ T lymphocytes after the fusion of this epitope to an antigen and immunization with the gene gun. We thus tested the cellular localization of the fusion proteins, position of the epitope on both ends of the antigen and the addition of flanking regions to the epitope that contain potential protease-sensitive sites.
For this analysis, we initially used the p30 epitope from the TT because it has been characterized as a strong universal (promiscuous) helper epitope that binds both human and mouse MHC class II molecules. 4, 7 This epitope has been shown to break the tolerance to a tumor self-antigen in a mouse model. 6 The analysis of CD4 þ T-cell reactivity of 100 human samples with p30 revealed recognition of the peptide by 86% of subjects. 17 It has been well documented that the cellular localization of an antigen produced from a DNA vaccine influences the activation of both CD8 þ and CD4 þ T cells. Targeting the HPV16 E7 oncoprotein into the endo/lysosomal compartment enhanced both arms of immunity. 21, 22 Therefore, we used sorting signals from LAMP-1 to target the E7GGG antigen derived from the HPV16 E7 oncoprotein into the endoplasmic reticulum and through the Golgi apparatus into the endo/lysosomal compartment. Such modifications of the E7 antigen enhanced the CTL response against E7, the effect being higher for the endo/ lysosomal targeting than for translocation into the endoplasmic reticulum only. 23 As we recorded similar data for E7GGG, we supposed that the addition of a foreign helper epitope might result in a superior efficacy of the E7GGG form with the endo/ lysosomal targeting. However, for this localization (and also for the delivery into the endoplasmic reticulum), the p30 epitope (in either form and molecular localization that was used) did not support the response of CD8 þ T cells measured in vitro by the production of IFN-g in an ELISPOT assay and in vivo by the treatment of tumors induced with TC-1 cells producing the E7 oncoprotein. 
Effect of helper epitopes on gene gun vaccination M Smahel et al
Thus, p30 significantly enhanced the E7-specific responses only for the natural nuclear/cytoplasmic localization of E7GGG and modified constructs. We considered several reasons why the effect of the p30 epitope on the stimulation of the E7-specific CTL response varied with the localization of antigens: (i) The cellular localization of antigens can affect their processing and presentation of individual epitopes. 24 However, similar levels of the specific-IFN-g-producing cells were found after stimulation with the TT 947-967 peptide in the ELISPOT assay for the antigens carrying p30 with the Effect of helper epitopes on gene gun vaccination M Smahel et al nuclear/cytoplasmic and endo/lysosomal localization. This suggests that at least for the endo/lysosomal localization, the lack of generation of the relevant TT peptide(s) is not responsible for the absence of CTL augmentation. (ii) N-glycosylation of the epitopes that occurs in the endoplasmic reticulum can influence their immunogenicity. 25, 26 We found a potential N-glycosylation site in the TT 947-967 peptide, but its abolition by the N949Q substitution did not influence the effect of the p30 epitope either in this study (data not shown) or in our immunization against legumain overexpressed in tumor macrophages (manuscript in preparation). (iii) The polarization of the T h response has a substantial effect on the CTL response. Gene gun immunization induces mixed T h 1/T h 2 immunity. 27 The monitoring of IL-10 and IL-13 productions after a 6-day restimulation showed that the T h 2 response specific for p30 was significantly promoted for the antigens translocated into the endoplasmic reticulum and the endo/lysosomal compartment, which was associated with the lack of enhancement of the response against E7. However, the cause of this augmented T h 2 activation is not still apparent. The balance between T h 1 and T h 2 immunity might be affected by different levels of direct priming and cross-priming of antigens with different cellular localization and/or stability, as direct priming preferentially induces the T h 1 response after vaccination with the gene gun. 28, 29 Moreover, various subsets of dendritic cells are involved in the activation of immune responses after gene gun immunization and these subsets induce differential polarization of T h cells, which may also be associated with a type of immunity priming 30 and influenced by cellular localization of an antigen.
As the conformation of an antigen molecule and residues flanking MHC class II-restricted epitopes can affect the processing of these epitopes, we examined the enlargement of the p30 epitope with flanking regions and localization of the epitope at both ends of the E7GGG antigen. For MHC class I-restricted epitopes, the fusion with the C-terminus of a carrier protein resulted in substantially stronger immunity than the N-terminal fusion because the processing of the C-terminus of the epitope can be a limiting step in epitope generation. 15 However, in our model system, the C-terminal fusion provided rather reduced immune responses, at least for the enlarged form of p30. Moreover, the addition of flanking residues did not enhance the immunogenicity in any position of the epitope and in any cellular localization of the fusion antigens.
In the subsequent experiments, we compared the effect of the p30 epitope with that of another universal helper epitope, the PADRE peptide. The latter epitope provided markedly higher specific induction of IFN-g-producing cells. This strong activation of T h cells was not limited to the nuclear/cytoplasmic localization of the fusion antigens but was exhibited for all cellular localizations and resulted in simultaneous enhancement of the E7-specific response and the antitumor effect. Analysis of IFN-g production after restimulation confirmed potent stimulation of theT h 1 immunity after vaccination with the three fusion constructs carrying PADRE. Moreover, the T h 2 reaction monitored by the determination of IL-13 production was significantly lower, especially after the translocation of the antigen into the endoplasmic reticulum. These results further support the notion that the inability of the p30 epitope to elevate the response against the E7 antigen after the translocation into the endoplasmic reticulum was associated with the relatively high activation of the T h 2 response.
Affinity of epitopes to MHC class II molecules affects the differential secretion of T h 1/T h 2 cytokines by CD4 þ T cells-their reduced affinity leads to preferential production of T h 2 cytokines.
31,32 Thus, we assume that the p30 epitope has lower affinity to MHC class II molecules in C57BL/6 mice than the PADRE epitope that fits well with both higher stimulation of IFN-g production by the PADRE epitope and stronger induction of IL-13 by the p30 epitope. The different ratio of the T h 1 versus T h 2 responses induced with the p30 and PADRE epitopes could lead to the different influence of cellular localization of the antigens with the helper epitopes on the E7-specific response: While the T h 2 response induced with the antigens translocated from the cytoplasm and carrying p30 was able to counterbalance the T h 1 response, the profoundly higher T h 1 response overcame the lower T h 2 response after immunization with the PADRE-containing antigens.
In concordance with our data, the PADRE epitope has been recently demonstrated to be more potent in the activation of IFN-g-producing T cells than the p30 epitope in C57BL/6 mice after tattoo delivery of DNA vaccines. 33 In that study, in difference to our results, modification of the E7 antigen with helper epitopes and with localization into the endoplasmic reticulum induced the strongest E7-specific immunity, which could suggest that our finding was specific for gene gun vaccination. However, besides a different method for DNA immunization, combination of three helper epitopes was used to achieve this effect. 33 In summary, we demonstrated that, although the cellular localization of the antigen produced by DNA vaccines delivered by the gene gun was crucial for the effect of the p30 helper epitope on the E7-specific response, the stronger immunity against the E7 antigen stimulated with the PADRE epitope was not noticeably dependent on this cellular localization. The higher potency of the PADRE epitope might be caused by its higher affinity to MHC class II molecules resulting in the observed stronger T h 1 and weaker T h 2 response in comparison with the p30 epitope. Our results point out that for antigens localized into the endoplasmic reticulum or endo/lysozomal compartment, the benefit of helper-epitope addition to DNA vaccines administered by the gene gun could be limited due to the enhancement of the T h 2 response.
MATERIALS AND METHODS
Cell lines
Tumorigenic TC-1 cells (kindly provided by T.-C. Wu, Johns Hopkins University, Baltimore, MD) were prepared by transformation of primary C57BL/6 mouse lung cells with the HPV16 E6/E7 oncogenes and activated H-ras. 22 NIH 3T3 fibroblasts established from mouse embryo culture 34 were obtained from the German National Resource Centre for Biological Material. Human embryonic kidney (HEK) 293T cells were kindly provided by J. Kleinschmidt, DKFZ, Heidelberg, Germany. Cells were grown in high-glucose Dulbecco's Modified Eagle's medium (DMEM; PAA Laboratories, Linz, Austria) supplemented with 10% fetal calf serum (PAA Laboratories), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
Plasmids
Plasmids pBSC/E7GGG 14 and pBSC/E7GGGLAMP (herein designated as pBSC/Sig.E7GGG.LAMP) 35 carrying the mutated oncogene E7 (E7GGG) were modified with TT-derived sequences (Figure 1 ). The sequences encoding the p30 epitope from the TT (aa 947-967; TT1s) or its extended form (aa 936-975, TT1l) were amplified from the codon-optimized sequence coding for the fragment C of the tetanus toxin. 36 These sequences were first inserted into the NsiI site at the 5 0 -terminus of E7GGG in both plasmids. From the plasmids with the signal sequence (Sig) and the LAMP sequence encoding the C-terminus of LAMP-1, the LAMP sequence was removed by amplification of the fusion genes with primers 5 0 -TGTGCTGTCTCATCATTTTG-3 0 (forward primer pBSC-F; it binds to the pBSC plasmid upstream of the cloned genes) and 5 0 -GTGAATTCTTATGGTTT CTGAGAACAGATGGGGCAC-3 0 (reverse primer which binds to the 3 0 -terminus of the E7GGG gene). For the fusion of TT1s and TT1l with the 3 0 -terminus of E7GGG and Sig.E7GGG, the NheI site was inserted upstream of the stop codon by amplification of the genes with the pBSC-F primer and the reverse primer 5 0 -GTGAATTCTTAGCTAGCTGGTTTCTGAGAACA GATG-3 0 (NheI site is underlined). The amplified genes were digested with EcoRI and cloned between the EcoRI sites of pBSC. Plasmids carrying fusion genes with a sequence coding for the PADRE epitope were prepared by the replacement of the TT1l-encoding sequence in the NsiI The sequence of all constructed genes was verified by DNA sequencing. Plasmids were propagated in Escherichia coli XL1-blue strain cultured in Luria Broth Medium with 100 mg/ml of ampicillin added and purified with the Qiagen Plasmid Maxi Kit (Qiagen, Hilden, Germany).
Peptides
The peptides (490% pure) E7 49-57 (RAHYNIVTF) and TT (FNNFTVSFWLRVPKVSASHLE) were custom synthesized by Clonestar Biotech (Brno, Czech Republic), and the PADRE peptide (AKFVAAWTLKAAA) was synthesized by GenScript (Piscataway, NJ, USA).
Mice
Seven-to eight-week-old female C57BL/6 mice (Charles River, Sulzfeld, Germany) were used in immunization experiments. Animals were maintained under standard conditions and in accordance with the guidelines for the proper treatment of laboratory animals at the Center for Experimental Biomodels, Charles University, Prague.
Immunofluorescence staining NIH 3T3 cells were grown on four-well Lab-Tek II Chamber Slides (Thermo Fisher Scientific, Waltham, MA, USA) and transfected with 0.5 mg of plasmids using the Lipofectamine 2000 Transfection Reagent (Invitrogen, Carlsbad, CA, USA). Two days after transfection, cells were fixed in 4% paraformaldehyde for 10 min and permeabilized in 0.2% Triton X-100 for 3 min at room temperature. The E7 antigen was stained with mouse monoclonal antibody (clone 8C9; Invitrogen) followed by Alexa Fluor 488-conjugated goat anti-mouse IgG antibodies (Invitrogen). The slides were examined by an Eclipse E600 microscope (Nikon, Tokyo, Japan).
Immunoblotting staining HEK 293T cells (10 6 ) seeded in 6-cm dishes were transfected with 6 mg of plasmids by calcium-phosphate precipitation in HEPES-buffered saline solution. Two days after transfection, the cells were washed with ice-cold phosphate-buffered saline and lysed in the 2x Laemmli buffer. Proteins separated by SDS-PAGE were electroblotted onto a polyvinylidene difluoride membrane (GE Healthcare, Little Chalfont, UK), incubated with E7-specific monoclonal antibody (Invitrogen) and, subsequently, with secondary peroxidase-labeled antibodies (GE Healthcare). Blots were stained using the enhanced chemiluminescence Plus detection system (GE Healthcare).
Immunization experiments
Plasmid DNA was coated onto 1-mm gold particles (Bio-Rad, Hercules, CA, USA) as described previously.
14 Mice were immunized with plasmids by a gene gun (Bio-Rad) at a discharge pressure of 400 psi into the shaven skin of the abdomen. Each immunization consisted of two shots delivering together 2 mg of plasmid DNA.
For in vitro examination of immune reactions, mice (three per group) were immunized with two doses of plasmids given 1 week apart. In therapeutic immunization against tumor cells, mice (six per group) were first subcutaneously (s.c.) inoculated with 3 Â 10 4 TC-1 cells into the back and then immunized with DNA vaccines 3, 7 and 10 days after cell inoculation. The empty pBSC plasmid was used as a negative control. Tumor cells were administered under anesthesia with intraperitoneal etomidate (0.5 mg per mouse; Janssen Pharmaceutica, Beerse, Belgium). Tumor growth was monitored twice a week and tumor size was calculated from three perpendicular measurements using the formula (p/6) (a Â b Â c).
ELISPOT assay A week after immunization, pooled splenocytes (three mice per group) were isolated, mononuclear cells were prepared by Ficoll-Paque (GE Healthcare) density gradient centrifugation and cells producing IFN-g were detected by the ELISPOT assay as described previously 37 with some modifications: 96-well filtration plates with a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA) were used and cells were cultured in serum-free CTL-test medium (CTL, Shaker Heights, OH, USA) with 0.1 mg/ml E7 49-57 peptide, 1 mg/ml TT 947-967 peptide or 1 mg/ml PADRE peptide overnight. Spots were evaluated by the ImmunoSpot S5 UV Lite Analyzer (CTL Analyzers LLC).
Quantification of cytokine production
The mononuclear cells prepared as for the ELISPOT assay were cultured in 1 ml of RPMI-1640 medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal calf serum, 1 mM pyruvate, 50 mM 2-mercaptoethanol, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin and restimulated with 1 mg/ml TT 947-967 peptide or PADRE peptide for 6 days. After 2 days of cultivation, 0.5 ml of complete medium with the peptides was added. Twelve cytokines in media were measured by Qiagen MultiAnalyte ELISArray and the production of IFN-g, IL-10 and IL-13 was determined by Ready-Set-Go! ELISA sets (eBioscience, San Diego, CA, USA).
Statistical analysis
Tumor formation was evaluated by the log-rank test and specific activation of lymphocytes determined in ELISPOT and production of cytokines by Student's t-test. Results were considered significantly different if Po0.05. Calculations were performed using the GraphPad Prism 5.2 software (GraphPad Software, San Diego, CA, USA).
